Key Points- Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial.- That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments.- But organizations representing insurers emphasized that the data is still preliminary, and concerns remain […]
